1. ZHAW digitalcollection
  2. School of Management and Law
  3. Publikationen
  4. Publikationen School of Management and Law
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVernaz, Nathalie-
dc.contributor.authorGirardin, François-
dc.contributor.authorGoossens, Nicolas-
dc.contributor.authorBrügger, Urs-
dc.contributor.authorRiguzzi, Marco-
dc.contributor.authorPerrier, Arnaud-
dc.contributor.authorNegro, Francesco-
dc.date.accessioned2018-11-23T10:40:33Z-
dc.date.available2018-11-23T10:40:33Z-
dc.date.issued2016-
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/13209-
dc.description.abstractObjective: We aimed to determine the association between the stepwise increase in the sustained viral response (SVR) and Swiss and United States (US) market prices of drug regimens for treatment-naive, genotype 1 chronic hepatitis C virus (HCV) infection in the last 25 years. Design: We performed a linear regression and a mean cost analysis to test for an association between SVRs and HCV regimen prices. We conducted a sensitivity analysis using US prices at the time of US drug licensing. We selected randomized clinical trials of drugs approved for use in Switzerland from 1997 to July 2015 including treatment-naïve patients with HCV genotype 1 infection. Conclusions: The pricing of drugs for HCV regimens follows a value-based model, which has a stable ratio of costs per achieved SVR over 25 years. Health care systems are struggling with the resource use of these new agents despite their long-term advantages for the overall health of the population. Therefore, the pharmaceutical industry, health care payers and other stakeholders are challenged with finding new drug pricing schemes to treat the entire population infected with HCV.de_CH
dc.language.isoende_CH
dc.rightsLicence according to publishing contractde_CH
dc.subject.ddc362: Gesundheits- und Sozialdienstede_CH
dc.titleHepatitis C infection drugs pricing : evolution over timede_CH
dc.typeKonferenz: Posterde_CH
dcterms.typeTextde_CH
zhaw.departementSchool of Management and Lawde_CH
zhaw.conference.detailsHTAi 2016 Annual Meeting, Tokyo, Japan, 10-14 May 2016de_CH
zhaw.funding.euNode_CH
zhaw.originated.zhawYesde_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.publication.reviewPeer review (Abstract)de_CH
Appears in collections:Publikationen School of Management and Law

Files in This Item:
There are no files associated with this item.
Show simple item record
Vernaz, N., Girardin, F., Goossens, N., Brügger, U., Riguzzi, M., Perrier, A., & Negro, F. (2016). Hepatitis C infection drugs pricing : evolution over time. HTAi 2016 Annual Meeting, Tokyo, Japan, 10-14 May 2016.
Vernaz, N. et al. (2016) ‘Hepatitis C infection drugs pricing : evolution over time’, in HTAi 2016 Annual Meeting, Tokyo, Japan, 10-14 May 2016.
N. Vernaz et al., “Hepatitis C infection drugs pricing : evolution over time,” in HTAi 2016 Annual Meeting, Tokyo, Japan, 10-14 May 2016, 2016.
VERNAZ, Nathalie, François GIRARDIN, Nicolas GOOSSENS, Urs BRÜGGER, Marco RIGUZZI, Arnaud PERRIER und Francesco NEGRO, 2016. Hepatitis C infection drugs pricing : evolution over time. In: HTAi 2016 Annual Meeting, Tokyo, Japan, 10-14 May 2016. Conference poster. 2016
Vernaz, Nathalie, François Girardin, Nicolas Goossens, Urs Brügger, Marco Riguzzi, Arnaud Perrier, and Francesco Negro. 2016. “Hepatitis C Infection Drugs Pricing : Evolution over Time.” Conference poster. In HTAi 2016 Annual Meeting, Tokyo, Japan, 10-14 May 2016.
Vernaz, Nathalie, et al. “Hepatitis C Infection Drugs Pricing : Evolution over Time.” HTAi 2016 Annual Meeting, Tokyo, Japan, 10-14 May 2016, 2016.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.